Bicocca Open Archive

Logo unimib boa
FALANGA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.528
AS - Asia 6.533
EU - Europa 4.623
SA - Sud America 1.223
Continente sconosciuto - Info sul continente non disponibili 689
AF - Africa 192
OC - Oceania 10
Totale 26.798
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.383
SG - Singapore 2.745
HK - Hong Kong 1.364
IT - Italia 1.258
RU - Federazione Russa 1.002
CA - Canada 996
BR - Brasile 913
CN - Cina 837
VN - Vietnam 666
IE - Irlanda 558
SE - Svezia 527
DE - Germania 480
FR - Francia 209
BD - Bangladesh 208
IN - India 171
GB - Regno Unito 161
AR - Argentina 108
AT - Austria 85
ID - Indonesia 81
UA - Ucraina 81
MX - Messico 68
IQ - Iraq 67
ZA - Sudafrica 59
NL - Olanda 52
TR - Turchia 52
EC - Ecuador 45
FI - Finlandia 45
PH - Filippine 44
PK - Pakistan 42
CO - Colombia 41
JP - Giappone 41
ES - Italia 38
SA - Arabia Saudita 35
KR - Corea 31
VE - Venezuela 31
MA - Marocco 29
PL - Polonia 25
CL - Cile 22
UZ - Uzbekistan 22
PE - Perù 20
PY - Paraguay 19
RO - Romania 19
TN - Tunisia 17
CR - Costa Rica 16
ET - Etiopia 16
JM - Giamaica 16
DK - Danimarca 15
DZ - Algeria 14
MY - Malesia 14
AE - Emirati Arabi Uniti 12
JO - Giordania 12
KE - Kenya 12
NP - Nepal 12
UY - Uruguay 12
BO - Bolivia 11
CH - Svizzera 11
EG - Egitto 10
IL - Israele 10
HN - Honduras 9
OM - Oman 9
TH - Thailandia 9
AU - Australia 8
KZ - Kazakistan 8
PT - Portogallo 8
AL - Albania 7
CZ - Repubblica Ceca 7
GR - Grecia 7
LB - Libano 7
MU - Mauritius 7
PA - Panama 7
DO - Repubblica Dominicana 6
EE - Estonia 6
NI - Nicaragua 6
SV - El Salvador 6
TT - Trinidad e Tobago 6
KG - Kirghizistan 5
KH - Cambogia 5
PS - Palestinian Territory 5
BA - Bosnia-Erzegovina 4
GE - Georgia 4
GT - Guatemala 4
IR - Iran 4
SN - Senegal 4
BY - Bielorussia 3
GA - Gabon 3
LY - Libia 3
RS - Serbia 3
AM - Armenia 2
AO - Angola 2
AZ - Azerbaigian 2
BE - Belgio 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
GP - Guadalupe 2
HU - Ungheria 2
LT - Lituania 2
ML - Mali 2
MM - Myanmar 2
NE - Niger 2
NZ - Nuova Zelanda 2
Totale 26.086
Salva come PNG Salva come JPEG
Città #
Singapore 1.403
Hong Kong 1.347
Ashburn 1.202
Ann Arbor 981
Fairfield 851
Toronto 802
San Jose 790
Dublin 553
Woodbridge 417
Milan 405
New York 382
Wilmington 378
Houston 376
Chandler 362
Dallas 341
Frankfurt am Main 333
Princeton 314
Cambridge 286
Santa Clara 272
Seattle 272
Chicago 267
Council Bluffs 250
Ho Chi Minh City 213
The Dalles 213
Hanoi 171
Beijing 167
Los Angeles 167
Jacksonville 146
Altamura 141
Lawrence 140
Lauterbourg 136
Boardman 114
Rome 114
Moscow 87
São Paulo 87
San Diego 82
Ottawa 81
Buffalo 63
Nuremberg 51
Vienna 48
Andover 46
Atlanta 43
Columbus 43
Phoenix 42
Shanghai 42
Orem 41
Jakarta 40
Brooklyn 36
London 35
Falls Church 32
Helsinki 32
Hefei 31
Salt Lake City 31
Tokyo 31
Rio de Janeiro 30
Baghdad 28
Figino 28
Montreal 28
Seoul 28
Brasília 26
Washington 26
Guangzhou 24
Nanjing 24
Redmond 24
Dearborn 22
Florence 22
Da Nang 21
Philadelphia 21
Tashkent 21
Charlotte 20
Dong Ket 20
Warsaw 20
Johannesburg 19
New Delhi 19
Dhaka 18
Haiphong 18
Norwalk 18
San Francisco 18
Tampa 18
Turin 16
Boston 15
Cape Town 15
Chennai 15
Denver 15
Detroit 15
Naples 15
Queens 15
Amsterdam 14
Ankara 14
Belo Horizonte 14
Campinas 14
Hải Dương 14
Lahore 14
Lancaster 14
Las Vegas 14
Newark 14
Paris 14
Quito 14
Addis Ababa 13
Delhi 13
Totale 16.192
Salva come PNG Salva come JPEG
Nome #
RECOMBINANT VERSUS HIGH-SENSITIVITY CONVENTIONAL THROMBOPLASTIN - A RANDOMIZED CLINICAL-STUDY IN PATIENTS ON ORAL ANTICOAGULATION 357
A microphysiological early metastatic niche on a chip reveals how heterotypic cell interactions and inhibition of integrin subunit β3 impact breast cancer cell extravasation 347
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 337
Fibrinolytic Proteins and Factor XIII as Predictors of Thrombotic and Hemorrhagic Complications in Hospitalized COVID-19 Patients 309
Treatment of venous thromboembolism with tinzaparin in oncological patients 309
Long-term outcomes of patients with cerebral vein thrombosis: a multicenter study 288
Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer 285
FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor 282
Prevention of venous thromboembolism in patients with cancer: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 271
Post-operative heparin reduces early venous thrombotic complications after orthotopic paediatric liver transplantation 266
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 265
Tissue Plasminogen Activator Levels and Risk of Breast Cancer in a Case-Cohort Study on Italian Women: Results from the Moli-sani Study 260
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 257
Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure 254
Thrombin generation predicts early recurrence in breast cancer patients 252
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update 243
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 230
Clozapine-induced anemia: A case-report 230
ISTH interim guidance on recognition and management of coagulopathy in COVID-19 225
The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH 224
Proceedings of the Second “International Conference on Thrombosis and Hemostasis Issues in Cancer”. September 19-21, 2003. Bergamo, Italy 221
Activated prothrombin complex concentrate (FEIBA ® ) in acquired haemophilia A: a large multicentre Italian study – the FAIR Registry 218
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs 216
Hemostatic biomarkers in occult cancer and cancer risk prediction 215
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 211
DOACs and “newer” hemophilia therapies in COVID-19: Reply 210
Pathophysiology 1. Mechanisms of Thrombosis in Cancer Patients 208
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry 208
Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome 208
Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia 207
Mechanisms and risk factors of thrombosis in cancer 206
Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE 206
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review 206
Anticoagulation in thrombocytopenic patients with hematological malignancy: A multinational clinical vignette-based experiment 205
Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research 201
Grey zones on the use of new oral anticoagulants in atrial fibrillation. Expert opinion [Grey zones sull'uso dei nuovi anticoagulanti orali nella fibrillazione atriale. Opinioni degli esperti] 201
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: Results of the prospective collaborative EPICA study 199
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine 198
Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper 197
Fundamental Research in Oncology and Thrombosis 2 (FRONTLINE 2): A Follow-Up Survey 197
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 195
Pathogenesis and treatment of thrombohemorrhagic diathesis in acute promyelocytic leukemia 193
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 193
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update Summary 192
THE HYPERCOAGULABLE STATE IN CANCER-PATIENTS - EVIDENCE FOR IMPAIRED THROMBIN INHIBITIONS 192
Managing Anti-Platelet Therapy in Thrombocytopaenic Patients with Haematological Malignancy: A Multinational Clinical Vignette-Based Experiment 189
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014 188
Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 186
Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery 186
Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus 185
Vitamin K-Dependent Procoagulant in Cancer Cells: A Potential Target for the Antimetastatic Effect of Warfarin? 185
Laboratory haemostasis monitoring in COVID-19 185
V. Plasmaferesi terapeutica 183
A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2 179
Unbalanced plasma control of TxA2 and PGI2 synthesis in Vitamin E deficient rats 178
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study 177
Association of plasma Protein C and CCL18 levels with neurodegenerative measures in Multiple Sclerosis patients 177
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera 176
Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study 175
The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia 173
The mechanisms of cancer-associated thrombosis 173
The effect of Vitamin E or selenium on the oxidant-antioxidant balance in rats 172
Molecular biomarkers of thrombosis in myeloproliferative neoplasms 172
Procoagulant mechanisms in tumour cells 171
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 170
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 170
Procoagulant activity of mouse transformed cells: Different expression in freshly isolated or cultured cells 170
Edoxaban for the treatment of cancer-associated venous thromboembolism 167
Venous thromboembolism in the hematologic malignancies 166
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study 166
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results 166
INEFFICACY OF INTRAVENOUS IMMUNOGLOBULIN IN PATIENTS WITH LOW-RISK THROMBOTIC THROMBOCYTOPENIC PURPURA/HEMOLYTIC-UREMIC SYNDROME 165
The prevention and management of asparaginase-related venous thromboembolism in adults: Guidance from the SSC on Hemostasis and Malignancy of the ISTH 165
Type and dose of heparin in Covid-19: Reply 165
The effect of very-low-dose warfarin on markers of hypercoagulation in metastatic breast cancer: Results from a randomized trial 163
External validation of the DASH prediction rule: a retrospective cohort study 163
Evaluation of nucleated red blood cell count by Sysmex XE-2100 in patients with thalassaemia or sickle cell anaemia and in neonates 162
Molecular basis for the relationship between thrombosis and cancer 161
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 161
Thrombophilic status may predict prognosis in patients with metastatic BRAFV600-mutated melanoma who are receiving BRAF inhibitors 158
Tromboxane synthetase inhibition results in increased platelet sensivity to prostacyclin. Thrombosis and Haemostasis 158
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 158
Antithrombotic medication in cancer-associated thrombocytopenia: Current evidence and knowledge gaps 157
The Italian START-Register on anticoagulation with focus on atrial fibrillation 157
Management of Cancer-associated Disseminated Intravascular Coagulation: guidance from the SSC of the ISTH 156
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation 156
Microparticles in tumor progression 156
Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis 155
Hemostatic biomarkers in cancer progression 155
International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER) 154
Eradication of acquired hemophilia associated with indolent non-Hodgkin lymphoma by a disease specific treatment 154
Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates 154
Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: The HYPERCAN study 153
Soluble stroma-related biomarkers of pancreatic cancer 152
An unexpected case of recurrence of pulmonary embolism in a patient recovered from COVID19 in full regimen dose of direct oral anticoagulant drug 151
Cancer and venous thromboembolism 148
L’uso del plasma 148
La coagulopatia indotta da trauma 148
Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid 147
Meeting Report EuroG20 Meeting on Cancer-Associated Thrombosis (CAT) Bergamo, Italy 7 April 2016 146
Totale 19.705
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.948
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.948
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.056 0 0 0 95 64 76 93 102 69 98 110 349
2022/20232.027 370 568 182 133 95 404 7 90 95 17 41 25
2023/20241.469 26 52 20 18 227 403 259 44 243 20 5 152
2024/20254.320 303 731 200 166 354 74 289 96 414 610 329 754
2025/20269.937 655 606 828 948 924 524 1.317 586 772 676 1.100 1.001
2026/20272.967 326 673 1.205 763 0 0 0 0 0 0 0 0
Totale 26.798